Phase 4 Atopic Dermatitis Research Study (28 Weeks)

Adults 18 years of age or older with chronic atopic dermatitis (AD) documented for at least 2 years prior to study start, may qualify to participate. Individuals must have an inadequate response to topical medications or otherwise be a candidate for systemic AD treatment. Moderate to severe atopic dermatitis must be present involving 10% or more of the body surface area. As part of the eligibility criteria, sleep quality and itch intensity will be assessed.

Participants will receive approved medication (active study drug) or placebo, via injection. Moisturizers and topical corticosteroids will be applied as background treatment during the study.

Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Participation will last about 28 weeks and involve about 10 visits to the study centre.

Call the study centre near you, or register now.

Learn more about
Atopic Dermatitis
Register Now!

Participating Locations

AR

  • Sorry no locations are available in this country.

CA

  • Sorry no locations are available in this country.

CL

  • Sorry no locations are available in this country.

MX

  • Sorry no locations are available in this country.

US

  • Sorry no locations are available in this country.

Register for
Active Studies!

Register

All information about you will be kept confidential.

If there are no active studies for your condition, we will keep your information and contact you when a new study starts in your area.

By registering you are consenting to the terms and conditions of our privacy policy.

Find the clinic near you:

Why Take Part In a Clinical Study?

Regulatory agencies like Health Canada, Australia's Therapeutic Goods Administration and the FDA require that Clinical Research Trials be conducted in order to develop new treatments, preventions and devices for diseases or conditions. Clinical Research Trials are also referred to as Clinical Studies or Clinical Trials. read more